Home > Animal Health and Nutrition > Veterinary Medical Devices > companion diagnostics market
Get a free sample of Companion Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Companion Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Some of the notable players operating in the companion diagnostics market are :
Industry players are adopting strategies such as new product launches, collaborations and mergers and acquisitions to grab high revenue share.
The market size of companion diagnostics exceeded USD 2 billion in 2018 and is poised to grow at over 19% CAGR between 2019 and 2025.
Hospital end-use segment dominated around 40% market share in 2018 owing to increasing patient pool due to high prevalence of chronic disorders.
North America market size is estimated to expand at more than 18% CAGR during the forecast timeline impelled by increasing prevalence of chronic diseases and growing geriatric population susceptible to these diseases.
Asia Pacific market revenue is anticipated to witness around 20.5% growth through 2025. Government initiatives for providing effective treatment to cancer patients will propel the regional market expansion.
Some of the notable players operating in the market are Roche, Pfizer, Merck, Astra Zeneca, Bristol Myers Squibb, Amgen, Biogen, Eli Lilly, Myriad Genetics, Johnson & Johnson, Becton, Dickinson and Company, and Abbott.